Dr Bruno Bockorny speaks to ecancer about the interim phase I results for denikitug, a novel anti-CCR8 monoclonal antibody designed to selectively deplete immunosuppressive regulatory T cells within the tumour microenvironment.

He explains that in this study, denikitug demonstrated clear pharmacologic activity, with robust depletion of CCR8-positive regulatory T cells and increased expansion of effector T cells, supporting its mechanism of enhancing antitumour immunity.

Early signs of clinical activity were observed across multiple tumour types, including responses in heavily pretreated patients and those previously exposed to PD-1/PD-L1 inhibitors.

The treatment was generally well tolerated, with mostly low-grade adverse events such as rash, pruritus, and fatigue, and no dose-limiting toxicities or high-grade safety concerns reported.

These findings support further development of denikitug both as monotherapy and in combination strategies aimed at overcoming resistance to immunotherapy.